{"id":2286,"date":"2020-11-17T22:33:32","date_gmt":"2020-11-17T22:33:32","guid":{"rendered":"\/\/smallcapscn.x5view.co\/?p=2286"},"modified":"2023-08-29T17:47:42","modified_gmt":"2023-08-29T17:47:42","slug":"investors-support-alterity-therapeutics-lead-drug-parkinsonian-diseases","status":"publish","type":"post","link":"https:\/\/smallcapscn.x5view.co\/?p=2286","title":{"rendered":"\u6295\u8d44\u8005\u652f\u6301Alterity Therapeutics\u7814\u53d1\u6cbb\u7597\u5e15\u91d1\u68ee\u75c5\u7684\u5148\u5bfc\u836f\u7269"},"content":{"rendered":"<p>\u6295\u8d44\u8005\u5df2\u7ecf\u4e3a<a href=\"http:\/\/smallcaps-production.test\/stocks\/?symbol=ATH&amp;lang=cn\">Alterity Therapeutics (ASX: ATH)<\/a>\u63d0\u4f9b\u4e863500\u4e07\u6fb3\u5143\u7684\u6295\u8d44\uff0c\u7528\u4e8e\u7814\u53d1\u6cbb\u7597\u5e15\u91d1\u68ee\u75c5(\u5c24\u5176\u662f\u591a\u53d1\u6027\u7cfb\u7edf\u840e\u7f29\u75c7(MSA))\u7684\u4e3b\u8981\u836f\u7269\u3002<\/p>\n<p>\u8be5\u516c\u53f8\u7684\u5148\u5bfc\u5316\u5408\u7269ATH434\u5438\u5f15\u4e86\u8d8a\u6765\u8d8a\u591a\u7684\u79d1\u5b66\u548c\u4e34\u5e8a\u5174\u8da3\uff0c\u6700\u8fd1\u7684\u878d\u8d44\u83b7\u5f97\u4e86\u6fb3\u5927\u5229\u4e9a\u3001\u7f8e\u56fd\u548c\u82f1\u56fd\u673a\u6784\u6295\u8d44\u8005\u7684\u8d44\u91d1\u3002<\/p>\n<p>\u5728\u63a5\u53d7<em>Small Cap<\/em>\u91c7\u8bbf\u65f6\uff0c \u8463\u4e8b\u957f\u517c\u9996\u5e2d\u6267\u884c\u5b98Geoffrey Kempler\u8868\u793a\uff0c\u4ed6\u5bf9\u516c\u53f8\u7684\u53d1\u5c55\u524d\u666f\u611f\u5230\u201c\u975e\u5e38\u5174\u594b\u201d\uff0c\u56e0\u4e3a\u80a1\u4e1c\u4eec\u610f\u8bc6\u5230\uff0c\u4ed6\u4eec\u7684\u94b1\u6295\u5728\u4e86\u201c\u806a\u660e\u3001\u8d1f\u8d23\u4efb\u3001\u4e45\u7ecf\u8003\u9a8c\u7684\u624b\u201d\u8eab\u4e0a\u3002<\/p>\n<p>\u4ed6\u8bf4\uff0cATH434\u6709\u201c\u5de8\u5927\u7684\u6f5c\u529b\u6765\u5e2e\u52a9\u5f88\u591a\u4eba\u201d\uff0c\u7279\u522b\u662f\u5f53\u201c\u5e15\u91d1\u68ee\u7597\u6cd5\u7684\u533b\u7597\u9700\u6c42\u65e0\u6cd5\u6ee1\u8db3\u201d\u7684\u65f6\u5019\u3002<\/p>\n<p>Kempler\u8868\u793a\uff0c\u4f5c\u4e3a\u786e\u4fddATH434\u6210\u529f\u7684\u6218\u7565\u7684\u4e00\u90e8\u5206\uff0c\u4ed6\u5df2\u7ecf\u7ec4\u5efa\u4e86\u4e00\u4e2a\u7531\u9996\u5e2d\u533b\u7597\u5b98David Stamler\u535a\u58eb\u9886\u5bfc\u7684\u201c\u56e2\u961f\u201d\u3002<\/p>\n<p>Kempler\u5148\u751f\u8bf4\uff0cStamler\u535a\u58eb\u4e4b\u524d\u5df2\u7ecf\u6210\u529f\u5730\u901a\u8fc7\u4e86\u7c7b\u4f3c\u836f\u7269\u7684\u8bd5\u9a8c\uff0c\u5e76\u83b7\u5f97\u4e86\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u7ba1\u7406\u5c40\u548c\u6b27\u6d32\u7684\u76d1\u7ba1\u673a\u6784\u7684\u6279\u51c6\u3002<\/p>\n<p>\u4ed6\u8865\u5145\u8bf4\uff0cStamler\u535a\u58eb\u9009\u62e9\u53c2\u4e0eATH434\u7684\u5f00\u53d1\uff0c\u6295\u8d44\u8005\u5bf9\u4ed6\u7684\u52a0\u5165\u611f\u5230\u201c\u6781\u5927\u7684\u5b89\u6170\u201d\u3002<\/p>\n<p>Alterity\u5df2\u7ecf\u5728\u6b27\u76df\u548c\u7f8e\u56fd\u83b7\u5f97\u4e86ATH434\u5b64\u513f\u836f\u7684\u5730\u4f4d\uff0c\u8fd9\u5bf9\u80a1\u4e1c\u6765\u8bf4\u662f\u5f88\u6709\u5229\u7684\u3002<\/p>\n<p>Kempler\u8868\u793a\uff0c\u968f\u7740Alterity\u5728ATH434\u65b9\u9762\u7684\u8fdb\u5c55\uff0c\u5176\u5b83\u5236\u836f\u516c\u53f8\u548c\u5229\u76ca\u76f8\u5173\u8005\u4e5f\u5728\u5bc6\u5207\u5173\u6ce8\u5b83\u3002<\/p>\n<h2>\u5173\u4e8eMSA<\/h2>\n<p>\u4f5c\u4e3a\u4e00\u79cd\u795e\u7ecf\u9000\u884c\u6027\u75be\u75c5\uff0cMSA\u7684\u8fd0\u52a8\u75c7\u72b6\u4e0e\u5e15\u91d1\u68ee\u6c0f\u75c7\u76f8\u4f3c\uff0c\u4f1a\u5bfc\u81f4\u8fd0\u52a8\u8fdf\u7f13\u3001\u50f5\u786c\u548c\u9707\u98a4\u3002MSA\u60a3\u8005\u5728\u75be\u75c5\u65e9\u671f\u8fd8\u5b58\u5728\u81ea\u4e3b\u8fd0\u52a8\u534f\u8c03\u6027\u964d\u4f4e\u548c\u6b65\u6001\u4e0d\u7a33\u5b9a\u3002<\/p>\n<p>\u5b83\u8fd8\u4f1a\u635f\u5bb3\u7ef4\u6301\u6b63\u5e38\u8840\u538b\u3001\u80a0\u9053\u529f\u80fd\u548c\u8180\u80f1\u63a7\u5236\u7684\u80fd\u529b\u3002<\/p>\n<p>\u8fd9\u79cd\u75be\u75c5\u5f80\u5f80\u572850\u5c81\u540e\u51fa\u73b0\u75c7\u72b6\u5e76\u8fc5\u901f\u53d1\u5c55\u3002\u968f\u7740\u75c5\u60c5\u53d1\u5c55\uff0c\u60a3\u8005\u8fd8\u4f1a\u51fa\u73b0\u541e\u54bd\u56f0\u96be\u3001\u58f0\u5e26\u762b\u75ea\u548c\u66f4\u5927\u7a0b\u5ea6\u7684\u4e0d\u6d3b\u52a8\u3002<\/p>\n<p>\u6700\u7ec8\u5bfc\u81f4\u4e25\u91cd\u6b8b\u75be\u548c\u6b7b\u4ea1\u3002<\/p>\n<p>Kempler\u6307\u51fa\uff0c\u76ee\u524d\u7684\u6cbb\u7597\u65b9\u6cd5\u5305\u62ec\u836f\u7269\u6cbb\u7597\u548c\u6539\u53d8\u751f\u6d3b\u65b9\u5f0f\u6765\u7ba1\u7406\u7cfb\u7edf\u3002\u7136\u800c\uff0c\u5bf9\u4e8e\u8fd9\u79cd\u201c\u6bc1\u706d\u6027\u201d\u75be\u75c5\u80cc\u540e\u7684\u6f5c\u5728\u539f\u56e0\uff0c\u76ee\u524d\u8fd8\u6ca1\u6709\u6cbb\u6108\u6216\u6cbb\u7597\u65b9\u6cd5\u3002<\/p>\n<h2>\u7b2c\u4e00\u9636\u6bb5\u8bd5\u9a8c\u7ed3\u679c<\/h2>\n<p>Alterity\u7684\u4e00\u671f\u7814\u7a76\u8bc4\u4f30\u4e86\u5065\u5eb7\u6210\u4eba\u548c\u8001\u5e74\u6210\u4eba\u5fd7\u613f\u8005\u7684\u5b89\u5168\u6027\u3001\u8010\u53d7\u6027\u548c\u836f\u4ee3\u52a8\u529b\u5b66\u3002<\/p>\n<p>\u7ed3\u679c\u663e\u793a\uff0cATH434\u53ef\u4ee5\u901a\u8fc7\u8840\u8111\u5c4f\u969c\uff0c\u540c\u65f6\u8010\u53d7\u826f\u597d\uff0c\u88ab\u8ba4\u4e3a\u662f\u5b89\u5168\u7684\u3002<\/p>\n<p>Alterity\u6b63\u8bd5\u56fe\u901a\u8fc7\u9776\u5411\u5bf9\u6b63\u5e38\u795e\u7ecf\u5143\u529f\u80fd\u81f3\u5173\u91cd\u8981\u7684- \u7a81\u89e6\u6838\u86cb\u767d\u6765\u6cbb\u7597MSA\u7684\u6f5c\u5728\u539f\u56e0\u3002\u901a\u8fc7\u53e3\u670d\uff0cATH434\u901a\u8fc7\u91cd\u65b0\u5206\u914d\u4e0d\u7a33\u5b9a\u7684\u94c1\uff0c\u4ece\u800c\u6291\u5236\u86cb\u767d\u8d28\u7684\u805a\u96c6\uff0c\u6d88\u9664\u6c27\u5316\u5e94\u6fc0\u7684\u6839\u672c\u539f\u56e0\u3002\u5728MSA\u52a8\u7269\u6a21\u578b\u4e2d\uff0cATH434\u4fdd\u5b58\u4e86\u795e\u7ecf\u5143\u5e76\u6539\u5584\u4e86\u8fd0\u52a8\u529f\u80fd\u3002<\/p>\n<p>\u5728\u5e15\u91d1\u68ee\u75c5\u548cMSA\u7b49\u60c5\u51b5\u4e0b\uff0c\u7a81\u89e6\u6838\u86cb\u767d\u805a\u96c6\uff0c\u5bfc\u81f4\u7ec6\u80de\u529f\u80fd\u969c\u788d\u548c\u6b7b\u4ea1\u3002\u6b63\u662f\u8fd9\u79cd\u795e\u7ecf\u635f\u4f24\u652f\u6491\u4e86\u591a\u53d1\u6027\u786c\u5316\u75c7\u7684\u75c7\u72b6\u3002<\/p>\n<p>Stamler\u535a\u58eb\u8bf4\uff0c\u8be5\u836f\u7269\u6709\u53ef\u80fd\u201c\u5f71\u54cd\u75be\u75c5\u7684\u5404\u4e2a\u65b9\u9762\u2014\u2014\u8fd0\u52a8\u75c7\u72b6\u3001\u8840\u538b\u95ee\u9898\u3001\u6b65\u6001\u548c\u5e73\u8861\uff0c\u751a\u81f3\u80a0\u9053\u548c\u8180\u80f1\u529f\u80fd\u969c\u788d\u201d\u3002<\/p>\n<h2>\u751f\u7269\u5229\u7528\u8bd5\u9a8c\u5de9\u56fa\u4e86\u4e8c\u671f\u7684\u6210\u529f<\/h2>\n<p>\u4e0a\u4e2a\u6708\u672b\uff0cAlterity\u5ba3\u5e03\uff0c\u5b83\u5df2\u7ecf\u5f00\u59cb\u5728\u7f8e\u56fd\u62db\u52dfMSA\u60a3\u8005\u53c2\u4e0e\u4e00\u9879\u751f\u7269\u5229\u7528\u7814\u7a76\uff0c\u8fd9\u9879\u7814\u7a76\u662f\u4e0e\u8303\u5fb7\u6bd4\u5c14\u7279\u5927\u5b66\u533b\u5b66\u4e2d\u5fc3\u5408\u4f5c\u8fdb\u884c\u7684\uff0c\u7531\u795e\u7ecf\u5b66\u526f\u6559\u6388\u3001\u9996\u5e2d\u7814\u7a76\u5458Daniel Claassen\u6307\u5bfc\u3002<\/p>\n<p>\u6839\u636eAlterity\u7684\u8bf4\u6cd5\uff0cbioMUSE\u662f\u4e00\u9879\u81ea\u7136\u5386\u53f2\u8bd5\u9a8c\uff0c\u5c06\u8ddf\u8e2aMSA\u60a3\u8005\u7684\u8fdb\u5c55\uff0c\u800c\u4e0d\u9700\u8981\u8fdb\u884c\u7814\u7a76\u6027\u836f\u7269\u6cbb\u7597\u3002<\/p>\n<p>\u80af\u666e\u52d2\u5148\u751f\u8bf4\uff0c\u8fd9\u9879\u7814\u7a76\u5c06\u4e3a\u660e\u5e74\u4e2d\u671f\u8ba1\u5212\u7684\u7b2c\u4e8c\u9636\u6bb5\u7814\u7a76\u63d0\u4f9b\u65e9\u671fMSA\u60a3\u8005\u7684\u201c\u91cd\u8981\u4fe1\u606f\u201d\u3002<\/p>\n<p>\u4ed6\u8865\u5145\u8bf4\uff0c\u901a\u8fc7\u786e\u5b9a\u5408\u9002\u7684\u7597\u6548\u7ec8\u70b9\u5e76\u8ddf\u8e2aMSA\u75c7\u72b6\u7684\u53d8\u5316\uff0c\u751f\u7269\u5229\u7528\u8bd5\u9a8c\u5c06\u964d\u4f4e\u4e8c\u671f\u7814\u7a76\u7684\u98ce\u9669\uff0c\u63d0\u9ad8\u5176\u6210\u529f\u7684\u673a\u4f1a\u3002<\/p>\n<p>\u9274\u4e8e\u7f3a\u4e4f\u6cbb\u7597MSA\u7684\u53ef\u7528\u7597\u6cd5\uff0c\u80af\u666e\u52d2\u4f30\u8ba1\uff0cATH434\u5355\u5728\u7f8e\u56fd\u7684\u9500\u552e\u989d\u5c31\u53ef\u80fd\u8fbe\u52305.5 &#8211; 7.25\u4ebf\u6fb3\u5143\u3002<\/p>\n<h2>\u6b63\u5728\u8fdb\u884c\u7684\u7814\u7a76\u548c\u53d1\u73b0<\/h2>\n<p>\u9664\u4e86ATH434\uff0cKempler\u5148\u751f\u8bf4\uff0cAlterity\u8fd8\u6709\u5176\u4ed6\u53ef\u80fd\u6cbb\u7597\u591a\u79cd\u75be\u75c5\u7684\u65b0\u836f\u7269\u3002<\/p>\n<p>\u76ee\u524d\uff0c\u8be5\u516c\u53f8\u6b63\u5728\u8bc4\u4f30\u5176\u836f\u7269PBT2\u4f5c\u4e3a\u6297\u83cc\u5242\u7684\u4f7f\u7528\u3002<\/p>\n<p>\u56e0\u6b64\uff0cKempler\u9884\u8ba1\uff0c\u968f\u7740Alterity\u7ee7\u7eed\u5176\u7814\u53d1\u4e4b\u65c5\uff0c\u8be5\u516c\u53f8\u5c06\u83b7\u5f97\u201c\u8bb8\u591a\u65b0\u7684\u6210\u529f\u201d\u3002<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u6295\u8d44\u8005\u5df2\u7ecf\u4e3aAlterity Therapeutics (ASX: ATH)\u63d0\u4f9b\u4e863500\u4e07\u6fb3\u5143\u7684\u6295\u8d44\uff0c\u7528\u4e8e\u7814\u53d1\u6cbb\u7597\u5e15\u91d1\u68ee\u75c5(\u5c24\u5176\u662f\u591a\u53d1\u6027\u7cfb\u7edf\u840e\u7f29\u75c7(MSA))\u7684\u4e3b\u8981\u836f\u7269\u3002 \u8be5\u516c\u53f8\u7684\u5148\u5bfc\u5316\u5408\u7269ATH434\u5438\u5f15\u4e86\u8d8a\u6765\u8d8a\u591a\u7684\u79d1\u5b66\u548c\u4e34\u5e8a\u5174\u8da3\uff0c\u6700\u8fd1\u7684\u878d\u8d44\u83b7\u5f97\u4e86\u6fb3\u5927\u5229\u4e9a\u3001\u7f8e\u56fd\u548c\u82f1\u56fd\u673a\u6784\u6295\u8d44\u8005\u7684\u8d44\u91d1\u3002 \u5728\u63a5\u53d7Small Cap\u91c7\u8bbf\u65f6\uff0c \u8463\u4e8b\u957f\u517c\u9996\u5e2d\u6267\u884c\u5b98Geoffrey Kempler\u8868\u793a\uff0c\u4ed6\u5bf9\u516c\u53f8\u7684\u53d1\u5c55\u524d\u666f\u611f\u5230\u201c\u975e\u5e38\u5174\u594b\u201d\uff0c\u56e0\u4e3a\u80a1\u4e1c\u4eec\u610f\u8bc6\u5230\uff0c\u4ed6\u4eec\u7684\u94b1\u6295\u5728\u4e86\u201c\u806a\u660e\u3001\u8d1f\u8d23\u4efb\u3001\u4e45\u7ecf\u8003\u9a8c\u7684\u624b\u201d\u8eab\u4e0a\u3002 \u4ed6\u8bf4\uff0cATH434\u6709\u201c\u5de8\u5927\u7684\u6f5c\u529b\u6765\u5e2e\u52a9\u5f88\u591a\u4eba\u201d\uff0c\u7279\u522b\u662f\u5f53\u201c\u5e15\u91d1\u68ee\u7597\u6cd5\u7684\u533b\u7597\u9700\u6c42\u65e0\u6cd5\u6ee1\u8db3\u201d\u7684\u65f6\u5019\u3002 Kempler\u8868\u793a\uff0c\u4f5c\u4e3a\u786e\u4fddATH434\u6210\u529f\u7684\u6218\u7565\u7684\u4e00\u90e8\u5206\uff0c\u4ed6\u5df2\u7ecf\u7ec4\u5efa\u4e86\u4e00\u4e2a\u7531\u9996\u5e2d\u533b\u7597\u5b98David Stamler\u535a\u58eb\u9886\u5bfc\u7684\u201c\u56e2\u961f\u201d\u3002 Kempler\u5148\u751f\u8bf4\uff0cStamler\u535a\u58eb\u4e4b\u524d\u5df2\u7ecf\u6210\u529f\u5730\u901a\u8fc7\u4e86\u7c7b\u4f3c\u836f\u7269\u7684\u8bd5\u9a8c\uff0c\u5e76\u83b7\u5f97\u4e86\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u7ba1\u7406\u5c40\u548c\u6b27\u6d32\u7684\u76d1\u7ba1\u673a\u6784\u7684\u6279\u51c6\u3002 \u4ed6\u8865\u5145\u8bf4\uff0cStamler\u535a\u58eb\u9009\u62e9\u53c2\u4e0eATH434\u7684\u5f00\u53d1\uff0c\u6295\u8d44\u8005\u5bf9\u4ed6\u7684\u52a0\u5165\u611f\u5230\u201c\u6781\u5927\u7684\u5b89\u6170\u201d\u3002 Alterity\u5df2\u7ecf\u5728\u6b27\u76df\u548c\u7f8e\u56fd\u83b7\u5f97\u4e86ATH434\u5b64\u513f\u836f\u7684\u5730\u4f4d\uff0c\u8fd9\u5bf9\u80a1\u4e1c\u6765\u8bf4\u662f\u5f88\u6709\u5229\u7684\u3002 Kempler\u8868\u793a\uff0c\u968f\u7740Alterity\u5728ATH434\u65b9\u9762\u7684\u8fdb\u5c55\uff0c\u5176\u5b83\u5236\u836f\u516c\u53f8\u548c\u5229\u76ca\u76f8\u5173\u8005\u4e5f\u5728\u5bc6\u5207\u5173\u6ce8\u5b83\u3002 \u5173\u4e8eMSA \u4f5c\u4e3a\u4e00\u79cd\u795e\u7ecf\u9000\u884c\u6027\u75be\u75c5\uff0cMSA\u7684\u8fd0\u52a8\u75c7\u72b6\u4e0e\u5e15\u91d1\u68ee\u6c0f\u75c7\u76f8\u4f3c\uff0c\u4f1a\u5bfc\u81f4\u8fd0\u52a8\u8fdf\u7f13\u3001\u50f5\u786c\u548c\u9707\u98a4\u3002MSA\u60a3\u8005\u5728\u75be\u75c5\u65e9\u671f\u8fd8\u5b58\u5728\u81ea\u4e3b\u8fd0\u52a8\u534f\u8c03\u6027\u964d\u4f4e\u548c\u6b65\u6001\u4e0d\u7a33\u5b9a\u3002 \u5b83\u8fd8\u4f1a\u635f\u5bb3\u7ef4\u6301\u6b63\u5e38\u8840\u538b\u3001\u80a0\u9053\u529f\u80fd\u548c\u8180\u80f1\u63a7\u5236\u7684\u80fd\u529b\u3002 \u8fd9\u79cd\u75be\u75c5\u5f80\u5f80\u572850\u5c81\u540e\u51fa\u73b0\u75c7\u72b6\u5e76\u8fc5\u901f\u53d1\u5c55\u3002\u968f\u7740\u75c5\u60c5\u53d1\u5c55\uff0c\u60a3\u8005\u8fd8\u4f1a\u51fa\u73b0\u541e\u54bd\u56f0\u96be\u3001\u58f0\u5e26\u762b\u75ea\u548c\u66f4\u5927\u7a0b\u5ea6\u7684\u4e0d\u6d3b\u52a8\u3002 \u6700\u7ec8\u5bfc\u81f4\u4e25\u91cd\u6b8b\u75be\u548c\u6b7b\u4ea1\u3002 Kempler\u6307\u51fa\uff0c\u76ee\u524d\u7684\u6cbb\u7597\u65b9\u6cd5\u5305\u62ec\u836f\u7269\u6cbb\u7597\u548c\u6539\u53d8\u751f\u6d3b\u65b9\u5f0f\u6765\u7ba1\u7406\u7cfb\u7edf\u3002\u7136\u800c\uff0c\u5bf9\u4e8e\u8fd9\u79cd\u201c\u6bc1\u706d\u6027\u201d\u75be\u75c5\u80cc\u540e\u7684\u6f5c\u5728\u539f\u56e0\uff0c\u76ee\u524d\u8fd8\u6ca1\u6709\u6cbb\u6108\u6216\u6cbb\u7597\u65b9\u6cd5\u3002 \u7b2c\u4e00\u9636\u6bb5\u8bd5\u9a8c\u7ed3\u679c Alterity\u7684\u4e00\u671f\u7814\u7a76\u8bc4\u4f30\u4e86\u5065\u5eb7\u6210\u4eba\u548c\u8001\u5e74\u6210\u4eba\u5fd7\u613f\u8005\u7684\u5b89\u5168\u6027\u3001\u8010\u53d7\u6027\u548c\u836f\u4ee3\u52a8\u529b\u5b66\u3002 \u7ed3\u679c\u663e\u793a\uff0cATH434\u53ef\u4ee5\u901a\u8fc7\u8840\u8111\u5c4f\u969c\uff0c\u540c\u65f6\u8010\u53d7\u826f\u597d\uff0c\u88ab\u8ba4\u4e3a\u662f\u5b89\u5168\u7684\u3002 Alterity\u6b63\u8bd5\u56fe\u901a\u8fc7\u9776\u5411\u5bf9\u6b63\u5e38\u795e\u7ecf\u5143\u529f\u80fd\u81f3\u5173\u91cd\u8981\u7684- \u7a81\u89e6\u6838\u86cb\u767d\u6765\u6cbb\u7597MSA\u7684\u6f5c\u5728\u539f\u56e0\u3002\u901a\u8fc7\u53e3\u670d\uff0cATH434\u901a\u8fc7\u91cd\u65b0\u5206\u914d\u4e0d\u7a33\u5b9a\u7684\u94c1\uff0c\u4ece\u800c\u6291\u5236\u86cb\u767d\u8d28\u7684\u805a\u96c6\uff0c\u6d88\u9664\u6c27\u5316\u5e94\u6fc0\u7684\u6839\u672c\u539f\u56e0\u3002\u5728MSA\u52a8\u7269\u6a21\u578b\u4e2d\uff0cATH434\u4fdd\u5b58\u4e86\u795e\u7ecf\u5143\u5e76\u6539\u5584\u4e86\u8fd0\u52a8\u529f\u80fd\u3002 \u5728\u5e15\u91d1\u68ee\u75c5\u548cMSA\u7b49\u60c5\u51b5\u4e0b\uff0c\u7a81\u89e6\u6838\u86cb\u767d\u805a\u96c6\uff0c\u5bfc\u81f4\u7ec6\u80de\u529f\u80fd\u969c\u788d\u548c\u6b7b\u4ea1\u3002\u6b63\u662f\u8fd9\u79cd\u795e\u7ecf\u635f\u4f24\u652f\u6491\u4e86\u591a\u53d1\u6027\u786c\u5316\u75c7\u7684\u75c7\u72b6\u3002 Stamler\u535a\u58eb\u8bf4\uff0c\u8be5\u836f\u7269\u6709\u53ef\u80fd\u201c\u5f71\u54cd\u75be\u75c5\u7684\u5404\u4e2a\u65b9\u9762\u2014\u2014\u8fd0\u52a8\u75c7\u72b6\u3001\u8840\u538b\u95ee\u9898\u3001\u6b65\u6001\u548c\u5e73\u8861\uff0c\u751a\u81f3\u80a0\u9053\u548c\u8180\u80f1\u529f\u80fd\u969c\u788d\u201d\u3002 \u751f\u7269\u5229\u7528\u8bd5\u9a8c\u5de9\u56fa\u4e86\u4e8c\u671f\u7684\u6210\u529f \u4e0a\u4e2a\u6708\u672b\uff0cAlterity\u5ba3\u5e03\uff0c\u5b83\u5df2\u7ecf\u5f00\u59cb\u5728\u7f8e\u56fd\u62db\u52dfMSA\u60a3\u8005\u53c2\u4e0e\u4e00\u9879\u751f\u7269\u5229\u7528\u7814\u7a76\uff0c\u8fd9\u9879\u7814\u7a76\u662f\u4e0e\u8303\u5fb7\u6bd4\u5c14\u7279\u5927\u5b66\u533b\u5b66\u4e2d\u5fc3\u5408\u4f5c\u8fdb\u884c\u7684\uff0c\u7531\u795e\u7ecf\u5b66\u526f\u6559\u6388\u3001\u9996\u5e2d\u7814\u7a76\u5458Daniel Claassen\u6307\u5bfc\u3002 \u6839\u636eAlterity\u7684\u8bf4\u6cd5\uff0cbioMUSE\u662f\u4e00\u9879\u81ea\u7136\u5386\u53f2\u8bd5\u9a8c\uff0c\u5c06\u8ddf\u8e2aMSA\u60a3\u8005\u7684\u8fdb\u5c55\uff0c\u800c\u4e0d\u9700\u8981\u8fdb\u884c\u7814\u7a76\u6027\u836f\u7269\u6cbb\u7597\u3002 \u80af\u666e\u52d2\u5148\u751f\u8bf4\uff0c\u8fd9\u9879\u7814\u7a76\u5c06\u4e3a\u660e\u5e74\u4e2d\u671f\u8ba1\u5212\u7684\u7b2c\u4e8c\u9636\u6bb5\u7814\u7a76\u63d0\u4f9b\u65e9\u671fMSA\u60a3\u8005\u7684\u201c\u91cd\u8981\u4fe1\u606f\u201d\u3002 \u4ed6\u8865\u5145\u8bf4\uff0c\u901a\u8fc7\u786e\u5b9a\u5408\u9002\u7684\u7597\u6548\u7ec8\u70b9\u5e76\u8ddf\u8e2aMSA\u75c7\u72b6\u7684\u53d8\u5316\uff0c\u751f\u7269\u5229\u7528\u8bd5\u9a8c\u5c06\u964d\u4f4e\u4e8c\u671f\u7814\u7a76\u7684\u98ce\u9669\uff0c\u63d0\u9ad8\u5176\u6210\u529f\u7684\u673a\u4f1a\u3002 \u9274\u4e8e\u7f3a\u4e4f\u6cbb\u7597MSA\u7684\u53ef\u7528\u7597\u6cd5\uff0c\u80af\u666e\u52d2\u4f30\u8ba1\uff0cATH434\u5355\u5728\u7f8e\u56fd\u7684\u9500\u552e\u989d\u5c31\u53ef\u80fd\u8fbe\u52305.5 &#8211; 7.25\u4ebf\u6fb3\u5143\u3002 \u6b63\u5728\u8fdb\u884c\u7684\u7814\u7a76\u548c\u53d1\u73b0 \u9664\u4e86ATH434\uff0cKempler\u5148\u751f\u8bf4\uff0cAlterity\u8fd8\u6709\u5176\u4ed6\u53ef\u80fd\u6cbb\u7597\u591a\u79cd\u75be\u75c5\u7684\u65b0\u836f\u7269\u3002 \u76ee\u524d\uff0c\u8be5\u516c\u53f8\u6b63\u5728\u8bc4\u4f30\u5176\u836f\u7269PBT2\u4f5c\u4e3a\u6297\u83cc\u5242\u7684\u4f7f\u7528\u3002 \u56e0\u6b64\uff0cKempler\u9884\u8ba1\uff0c\u968f\u7740Alterity\u7ee7\u7eed\u5176\u7814\u53d1\u4e4b\u65c5\uff0c\u8be5\u516c\u53f8\u5c06\u83b7\u5f97\u201c\u8bb8\u591a\u65b0\u7684\u6210\u529f\u201d\u3002<\/p>\n","protected":false},"author":3,"featured_media":10067,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[3],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v17.3 (Yoast SEO v21.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>\u6295\u8d44\u8005\u652f\u6301Alterity Therapeutics\u7814\u53d1\u6cbb\u7597\u5e15\u91d1\u68ee\u75c5\u7684\u5148\u5bfc\u836f\u7269<\/title>\n<meta name=\"description\" content=\"\u6295\u8d44\u8005\u5df2\u7ecf\u4e3aAlterity Therapeutics (ASX: ATH)\u63d0\u4f9b\u4e863500\u4e07\u6fb3\u5143\u7684\u6295\u8d44\uff0c\u7528\u4e8e\u7814\u53d1\u6cbb\u7597\u5e15\u91d1\u68ee\u75c5(\u5c24\u5176\u662f\u591a\u53d1\u6027\u7cfb\u7edf\u840e\u7f29\u75c7(MSA))\u7684\u4e3b\u8981\u836f\u7269\u3002\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u6295\u8d44\u8005\u652f\u6301Alterity Therapeutics\u7814\u53d1\u6cbb\u7597\u5e15\u91d1\u68ee\u75c5\u7684\u5148\u5bfc\u836f\u7269\" \/>\n<meta property=\"og:description\" content=\"\u6295\u8d44\u8005\u5df2\u7ecf\u4e3aAlterity Therapeutics (ASX: ATH)\u63d0\u4f9b\u4e863500\u4e07\u6fb3\u5143\u7684\u6295\u8d44\uff0c\u7528\u4e8e\u7814\u53d1\u6cbb\u7597\u5e15\u91d1\u68ee\u75c5(\u5c24\u5176\u662f\u591a\u53d1\u6027\u7cfb\u7edf\u840e\u7f29\u75c7(MSA))\u7684\u4e3b\u8981\u836f\u7269\u3002\" \/>\n<meta property=\"og:url\" content=\"https:\/\/smallcapscn.x5view.co\/investors-support-alterity-therapeutics-lead-drug-parkinsonian-diseases\/\" \/>\n<meta property=\"og:site_name\" content=\"smallcapsCN\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-17T22:33:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-29T17:47:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/smallcapscn.x5view.co\/wp-content\/uploads\/2023\/08\/Alterity-Therapeutics-Parkinsonian-diseases-multiple-system-atrophy-MSA-ASX-ATH.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Lorna Nicholas\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"\u6295\u8d44\u8005\u652f\u6301Alterity Therapeutics\u7814\u53d1\u6cbb\u7597\u5e15\u91d1\u68ee\u75c5\u7684\u5148\u5bfc\u836f\u7269\" \/>\n<meta name=\"twitter:description\" content=\"\u6295\u8d44\u8005\u5df2\u7ecf\u4e3aAlterity Therapeutics (ASX: ATH)\u63d0\u4f9b\u4e863500\u4e07\u6fb3\u5143\u7684\u6295\u8d44\uff0c\u7528\u4e8e\u7814\u53d1\u6cbb\u7597\u5e15\u91d1\u68ee\u75c5(\u5c24\u5176\u662f\u591a\u53d1\u6027\u7cfb\u7edf\u840e\u7f29\u75c7(MSA))\u7684\u4e3b\u8981\u836f\u7269\u3002\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Lorna Nicholas\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/investors-support-alterity-therapeutics-lead-drug-parkinsonian-diseases\/\",\"url\":\"https:\/\/smallcapscn.x5view.co\/investors-support-alterity-therapeutics-lead-drug-parkinsonian-diseases\/\",\"name\":\"\u6295\u8d44\u8005\u652f\u6301Alterity Therapeutics\u7814\u53d1\u6cbb\u7597\u5e15\u91d1\u68ee\u75c5\u7684\u5148\u5bfc\u836f\u7269\",\"isPartOf\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\"},\"datePublished\":\"2020-11-17T22:33:32+00:00\",\"dateModified\":\"2023-08-29T17:47:42+00:00\",\"author\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/3e816860d3443582b1918467347eeb60\"},\"description\":\"\u6295\u8d44\u8005\u5df2\u7ecf\u4e3aAlterity Therapeutics (ASX: ATH)\u63d0\u4f9b\u4e863500\u4e07\u6fb3\u5143\u7684\u6295\u8d44\uff0c\u7528\u4e8e\u7814\u53d1\u6cbb\u7597\u5e15\u91d1\u68ee\u75c5(\u5c24\u5176\u662f\u591a\u53d1\u6027\u7cfb\u7edf\u840e\u7f29\u75c7(MSA))\u7684\u4e3b\u8981\u836f\u7269\u3002\",\"breadcrumb\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/investors-support-alterity-therapeutics-lead-drug-parkinsonian-diseases\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/smallcapscn.x5view.co\/investors-support-alterity-therapeutics-lead-drug-parkinsonian-diseases\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/investors-support-alterity-therapeutics-lead-drug-parkinsonian-diseases\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/smallcapscn.x5view.co\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u6295\u8d44\u8005\u652f\u6301Alterity Therapeutics\u7814\u53d1\u6cbb\u7597\u5e15\u91d1\u68ee\u75c5\u7684\u5148\u5bfc\u836f\u7269\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\",\"url\":\"https:\/\/smallcapscn.x5view.co\/\",\"name\":\"smallcapsCN\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/3e816860d3443582b1918467347eeb60\",\"name\":\"Lorna Nicholas\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/431dd83ad861252293034fed39d5d7a5?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/431dd83ad861252293034fed39d5d7a5?s=96&d=mm&r=g\",\"caption\":\"Lorna Nicholas\"},\"description\":\"Lorna has more than 15 years' experience as a business\/finance journalist and editor. She has written for numerous industry publications reporting on various sectors, including: resources, energy, construction, biotech, pharma, science and technology, agriculture, and chemicals. Specialising in resources, Lorna has also covered a myriad of small and large cap ASX and dual-listed stocks.\",\"url\":\"https:\/\/smallcapscn.x5view.co\/?author=3\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"\u6295\u8d44\u8005\u652f\u6301Alterity Therapeutics\u7814\u53d1\u6cbb\u7597\u5e15\u91d1\u68ee\u75c5\u7684\u5148\u5bfc\u836f\u7269","description":"\u6295\u8d44\u8005\u5df2\u7ecf\u4e3aAlterity Therapeutics (ASX: ATH)\u63d0\u4f9b\u4e863500\u4e07\u6fb3\u5143\u7684\u6295\u8d44\uff0c\u7528\u4e8e\u7814\u53d1\u6cbb\u7597\u5e15\u91d1\u68ee\u75c5(\u5c24\u5176\u662f\u591a\u53d1\u6027\u7cfb\u7edf\u840e\u7f29\u75c7(MSA))\u7684\u4e3b\u8981\u836f\u7269\u3002","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"\u6295\u8d44\u8005\u652f\u6301Alterity Therapeutics\u7814\u53d1\u6cbb\u7597\u5e15\u91d1\u68ee\u75c5\u7684\u5148\u5bfc\u836f\u7269","og_description":"\u6295\u8d44\u8005\u5df2\u7ecf\u4e3aAlterity Therapeutics (ASX: ATH)\u63d0\u4f9b\u4e863500\u4e07\u6fb3\u5143\u7684\u6295\u8d44\uff0c\u7528\u4e8e\u7814\u53d1\u6cbb\u7597\u5e15\u91d1\u68ee\u75c5(\u5c24\u5176\u662f\u591a\u53d1\u6027\u7cfb\u7edf\u840e\u7f29\u75c7(MSA))\u7684\u4e3b\u8981\u836f\u7269\u3002","og_url":"https:\/\/smallcapscn.x5view.co\/investors-support-alterity-therapeutics-lead-drug-parkinsonian-diseases\/","og_site_name":"smallcapsCN","article_published_time":"2020-11-17T22:33:32+00:00","article_modified_time":"2023-08-29T17:47:42+00:00","og_image":[{"width":640,"height":400,"url":"https:\/\/smallcapscn.x5view.co\/wp-content\/uploads\/2023\/08\/Alterity-Therapeutics-Parkinsonian-diseases-multiple-system-atrophy-MSA-ASX-ATH.jpg","type":"image\/jpeg"}],"author":"Lorna Nicholas","twitter_card":"summary_large_image","twitter_title":"\u6295\u8d44\u8005\u652f\u6301Alterity Therapeutics\u7814\u53d1\u6cbb\u7597\u5e15\u91d1\u68ee\u75c5\u7684\u5148\u5bfc\u836f\u7269","twitter_description":"\u6295\u8d44\u8005\u5df2\u7ecf\u4e3aAlterity Therapeutics (ASX: ATH)\u63d0\u4f9b\u4e863500\u4e07\u6fb3\u5143\u7684\u6295\u8d44\uff0c\u7528\u4e8e\u7814\u53d1\u6cbb\u7597\u5e15\u91d1\u68ee\u75c5(\u5c24\u5176\u662f\u591a\u53d1\u6027\u7cfb\u7edf\u840e\u7f29\u75c7(MSA))\u7684\u4e3b\u8981\u836f\u7269\u3002","twitter_misc":{"Written by":"Lorna Nicholas"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/smallcapscn.x5view.co\/investors-support-alterity-therapeutics-lead-drug-parkinsonian-diseases\/","url":"https:\/\/smallcapscn.x5view.co\/investors-support-alterity-therapeutics-lead-drug-parkinsonian-diseases\/","name":"\u6295\u8d44\u8005\u652f\u6301Alterity Therapeutics\u7814\u53d1\u6cbb\u7597\u5e15\u91d1\u68ee\u75c5\u7684\u5148\u5bfc\u836f\u7269","isPartOf":{"@id":"https:\/\/smallcapscn.x5view.co\/#website"},"datePublished":"2020-11-17T22:33:32+00:00","dateModified":"2023-08-29T17:47:42+00:00","author":{"@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/3e816860d3443582b1918467347eeb60"},"description":"\u6295\u8d44\u8005\u5df2\u7ecf\u4e3aAlterity Therapeutics (ASX: ATH)\u63d0\u4f9b\u4e863500\u4e07\u6fb3\u5143\u7684\u6295\u8d44\uff0c\u7528\u4e8e\u7814\u53d1\u6cbb\u7597\u5e15\u91d1\u68ee\u75c5(\u5c24\u5176\u662f\u591a\u53d1\u6027\u7cfb\u7edf\u840e\u7f29\u75c7(MSA))\u7684\u4e3b\u8981\u836f\u7269\u3002","breadcrumb":{"@id":"https:\/\/smallcapscn.x5view.co\/investors-support-alterity-therapeutics-lead-drug-parkinsonian-diseases\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/smallcapscn.x5view.co\/investors-support-alterity-therapeutics-lead-drug-parkinsonian-diseases\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/smallcapscn.x5view.co\/investors-support-alterity-therapeutics-lead-drug-parkinsonian-diseases\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/smallcapscn.x5view.co\/"},{"@type":"ListItem","position":2,"name":"\u6295\u8d44\u8005\u652f\u6301Alterity Therapeutics\u7814\u53d1\u6cbb\u7597\u5e15\u91d1\u68ee\u75c5\u7684\u5148\u5bfc\u836f\u7269"}]},{"@type":"WebSite","@id":"https:\/\/smallcapscn.x5view.co\/#website","url":"https:\/\/smallcapscn.x5view.co\/","name":"smallcapsCN","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/3e816860d3443582b1918467347eeb60","name":"Lorna Nicholas","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/431dd83ad861252293034fed39d5d7a5?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/431dd83ad861252293034fed39d5d7a5?s=96&d=mm&r=g","caption":"Lorna Nicholas"},"description":"Lorna has more than 15 years' experience as a business\/finance journalist and editor. She has written for numerous industry publications reporting on various sectors, including: resources, energy, construction, biotech, pharma, science and technology, agriculture, and chemicals. Specialising in resources, Lorna has also covered a myriad of small and large cap ASX and dual-listed stocks.","url":"https:\/\/smallcapscn.x5view.co\/?author=3"}]}},"_links":{"self":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/2286"}],"collection":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2286"}],"version-history":[{"count":1,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/2286\/revisions"}],"predecessor-version":[{"id":10066,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/2286\/revisions\/10066"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/media\/10067"}],"wp:attachment":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2286"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2286"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2286"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}